Researcher
Sandrine Aspeslagh
- Keywords:Medicine
Affiliations
- Internal medicine (Department)
Member
From1 May 2023 → Today - Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Medical Oncology (Department)
Member
From1 Feb 2019 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → 20 Oct 2022 - Clinical sciences (Department)
Member
From15 Nov 2020 → 14 Nov 2022
Projects
1 - 1 of 1
- FORX - FOod interventions to Reduce immunotherapy toXicityFrom1 Nov 2023 → TodayFunding: FWO fellowships
Publications
41 - 50 of 71
- Epigenetic modifiers as new immunomodulatory therapies in solid tumours(2018)
Authors: Sandrine Aspeslagh, D Morel, Jean-Charles Soria, Sophie Postel-Vinay
Pages: 812-824 - Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy(2018)
Authors: Sébastien Le Burel, Stéphane Champiat, Emilie Routier, Sandrine Aspeslagh, Laurence Albiges, Tali-Anne Szwebel, Jean-Marie Michot, Pascale Chretien, Xavier Mariette, Anne-Laure Voisin, et al.
Pages: 468-470 - Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease(2018)
Authors: François-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, Jean-Marie Michot, Emilie Routier, Laurent Taillade, Stéphane Champiat, Sandrine Aspeslagh, Julien Haroche, Laurence Albiges, et al.
Pages: 21-29 - Are phase I trials safe for older patients?(2018)
Authors: Capucine Baldini, Olivia Le Saux, Carole Helissey, Sandrine Aspeslagh, Eduardo Castanon, Andrea Varga, Anas Gazzah, Rastilav Bahleda, Olivier Mir, Christophe Massard, et al.
Pages: 87-92 - In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?(2017)
Authors: Sandrine Aspeslagh, Margarida Matias, Virginia Palomar, Laurent Dercle, Emilie Lanoy, Jean-Charles Soria, Sophie Postel-Vinay
Pages: 65-74 - Challenges and perspectives in the immunotherapy of Hodgkin lymphoma(2017)
Authors: Jean-Marie Michot, Julien Lazarovici, David Ghez, Alina Danu, Christophe Fermé, Amélie Bigorgne, Vincent Ribrag, Aurélien Marabelle, Sandrine Aspeslagh
Pages: 67-77 - Prospective validation of a prognostic score for patients in immunotherapy phase I trials(2017)
Authors: Frédéric Bigot, Eduardo Castanon, Capucine Baldini, Antoine Hollebecque, Alberto Carmona, Sophie Postel-Vinay, Eric Angevin, Jean-Pierre Armand, Vincent Ribrag, Sandrine Aspeslagh, et al.
Pages: 212-218 - Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)(2017)
Authors: Roger Sun, Stéphane Champiat, Laurent Dercle, Sandrine Aspeslagh, Eduardo Castanon, Elaine Johanna Limkin, Capucine Baldini, Sophie Postel-Vinay, Antoine Hollebecque, Christophe Massard, et al.
Pages: 202-211 - TILs in Head and Neck Cancer(2017)
Authors: Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Katrien Vandecasteele, Sylvie Rottey, Liesbeth Ferdinande
Pages: 354-363 - RECIST response and variation of circulating tumour cells in phase 1 trials(2017)
Authors: Christophe Massard, Isabelle Borget, Françoise Farace, Sandrine Aspeslagh, Marie-Cécile Le Deley, Christophe Le Tourneau, François-Clement Bidard, Jean-Yves Pierga, Veronique Dieras, Paul L Hofman, et al.
Pages: 185-193